# BTG1

Source: https://onco.cc/targets/btg1/  
OnCo record `btg1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.

## Summary

Anti-proliferative protein.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, animal model 0.47, genetic association 0.28, somatic mutation 0.79). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: BTG anti-proliferation factor 1; APRO2
- Tags: cancer-genes-wave
- Symbol: BTG1
- Class: tumor-suppressor
- Biology: Anti-proliferative protein. Locus 12q21.33 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.67 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL); Multiple myeloma: IntOGen driver in 1 cohort (PCM); Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease; Chronic lymphocytic leukaemia: IntOGen driver in 1 cohort (CLLSLL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1130: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1130
- UniProt P62324: https://www.uniprot.org/uniprotkb/P62324/entry
- NCBI Gene 694: https://www.ncbi.nlm.nih.gov/gene/694
- Ensembl ENSG00000133639: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133639

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/btg1.json